Insulin commercialization

Articles Galleries Videos
  • Biocon, Kiran Mazumdar-Shaw, biocon recommends a dividend of rs 5 per share, Insulin commercialization

    Biocon recommends a dividend of Rs. 5 per share  28 April 2012

    Biocon posts Revenues at Rs 2,148 Crores;   EBITDA at Rs 579 Crores;   PAT at Rs 338 Crores Commenting on the results, Chairman and Managing Director of Biocon Kiran Mazumdar-Shaw stated, “I am pleased with the overall performance that we have...

    Keywords: net licensing income, Biocon Research Center, Research Services & Branded Formulations, net licensing income

    Read More